1 Vancouver General Hospital , Vancouver, Canada .
2 University of British Columbia , Vancouver, Canada .
J Womens Health (Larchmt). 2017 Nov;26(11):1185-1192. doi: 10.1089/jwh.2016.5984. Epub 2017 Apr 6.
Patients with acute myocardial infarction (MI) and nonobstructive coronary artery disease (CAD) have an elevated cardiac event rate, suggesting that these patients may benefit from cardiac medication.
We evaluated the rates of cardiac medication use 3 months before angiography and 3 months following clinically indicated angiography for MI in patients with no CAD, nonobstructive CAD, and obstructive CAD. We also examined the sex differences in cardiac medication use 3 months following angiography in patients by extent of angiographic CAD.
We studied patients ≥20 years old with MI undergoing coronary angiography in British Columbia, Canada, from January 1, 2008, to March 31, 2010 (n = 3,841). No CAD, nonobstructive CAD, and obstructive CAD were defined as 0%, 1% to 49%, and ≥50% luminal narrowing in any epicardial coronary artery, respectively. Medication use, 3 months before and 3 months following angiography, was obtained through British Columbia PharmaNet for angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), beta-blockers, statins, and antiplatelet agents. Optimal medical therapy (OMT) was defined as filled prescriptions for all three: ACE-Is/ARBs, beta-blockers, and statins.
Following angiography, in all medication categories except CCBs, patients with no CAD and nonobstructive CAD had significantly lower rates of prescriptions filled than patients with obstructive CAD (all p < 0.001). After adjusting for age and prior medication use, patients with nonobstructive CAD were still less likely to receive these medications than patients with obstructive CAD, including OMT with an odds ratio = 0.25 (95% confidence interval: 0.18-0.36). There were no significant sex differences in medication use 3 months postangiography.
In post-MI patients, medication use following angiography is significantly lower in nonobstructive CAD than obstructive CAD at 3 months. While sex was not an independent predictor of medication use 3 months post-catheterization, future studies should explore methods of improving medication use in both females and males with nonobstructive CAD post-MI.
急性心肌梗死(MI)和非阻塞性冠状动脉疾病(CAD)患者的心脏事件发生率升高,表明这些患者可能受益于心脏药物治疗。
我们评估了无 CAD、非阻塞性 CAD 和阻塞性 CAD 的 MI 患者在血管造影前 3 个月和临床指示血管造影后 3 个月的心脏药物使用情况。我们还检查了根据血管造影 CAD 程度,血管造影后 3 个月患者心脏药物使用的性别差异。
我们研究了 2008 年 1 月 1 日至 2010 年 3 月 31 日期间在加拿大不列颠哥伦比亚省接受冠状动脉造影的≥20 岁 MI 患者(n=3841)。无 CAD、非阻塞性 CAD 和阻塞性 CAD 分别定义为任何心外膜冠状动脉中 0%、1%至 49%和≥50%的管腔狭窄。通过不列颠哥伦比亚省 PharmaNet 获得血管造影前 3 个月和后 3 个月的药物使用情况,包括血管紧张素转换酶抑制剂(ACE-Is)、血管紧张素受体阻滞剂(ARBs)、钙通道阻滞剂(CCBs)、β受体阻滞剂、他汀类药物和抗血小板药物。最佳药物治疗(OMT)定义为所有三种药物的处方:ACE-Is/ARBs、β受体阻滞剂和他汀类药物。
在所有药物类别中(除 CCB 外),无 CAD 和非阻塞性 CAD 患者的药物处方率明显低于阻塞性 CAD 患者(均 p<0.001)。调整年龄和既往用药后,非阻塞性 CAD 患者仍比阻塞性 CAD 患者更不可能接受这些药物治疗,包括 OMT 的比值比=0.25(95%置信区间:0.18-0.36)。血管造影后 3 个月,药物使用的性别差异无统计学意义。
在 MI 后患者中,血管造影后 3 个月非阻塞性 CAD 患者的药物使用明显低于阻塞性 CAD。尽管性别不是血管造影后 3 个月药物使用的独立预测因素,但未来的研究应探索改善 MI 后非阻塞性 CAD 患者中女性和男性药物使用的方法。